The Beneficial Effect of Donepezil on Visual Hallucinations in Three Patients with Parkinson's Disease

Journal of Geriatric Psychiatry and Neurology

Volumn 16, Issue 3, 2003, Pages 184-188

  Kurita, Akira ^a   Ochiai, Yusuke ^a   Kono, Yu ^a   Suzuki, Masahiko ^a   Inoue, Kiyoharu ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acetylcholinesterese inhibitor; Cognitive impairment; Donepezil; Motor functions; Parkinson's disease; Visual hallucinations

Indexed keywords

ANTIPARKINSON AGENT; BENSERAZIDE; BROMOCRIPTINE MESILATE; CARBIDOPA; CHOLINESTERASE INHIBITOR; DIAZEPAM; DONEPEZIL; HALOPERIDOL; LEVODOPA; NEUROLEPTIC AGENT; SELEGILINE; THREO 3,4 DIHYDROXYPHENYLSERINE; TRIHEXYPHENIDYL;

ADULT; AGED; ARTICLE; CASE REPORT; CHRONIC DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; DELUSION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; MOTOR DYSFUNCTION; NEUROPSYCHOLOGICAL TEST; OUTCOMES RESEARCH; PARKINSON DISEASE; PRIORITY JOURNAL; SCORING SYSTEM; SYMPTOM; VISUAL HALLUCINATION;

AGED; AGED, 80 AND OVER; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; FEMALE; HALLUCINATIONS; HUMANS; INDANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PIPERIDINES; PSYCHOMOTOR DISORDERS; SEVERITY OF ILLNESS INDEX;

EID: 0242511882     PISSN: 08919887     EISSN: None     Source Type: Journal    
DOI: 10.1177/0891988703256054     Document Type: Article

References (22)

1. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993; 42:2227-2229.
2. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 56(suppl 5):S1-S88.
3. Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease. Lancet 1994; 344:681.
4. Mohr E, Hildebrand K, Mendis T, De Deyn PP. Worsening of motor function in Parkinson's disease: a "typical" response to "atypical" antipsychotic medications. Neurology 2001; 56:1249-1250.
5. Shea C, MacKnight C, Rockwood K. Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 1998; 10:229-238.
6. Lanctõt KL, Herrmann N. Donepezil for behavioural disorders associated with Lewy bodies: a case series. Int Geriatr Psychiatry 2000; 15:338-345.
7. Samuel W, Caligiuri M, Galasko D, et al. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int Geriatr Psychiatry 2000; 15:794-802.
8. Folstein MS, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 1975; 12:189-198.
9. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease. Vol. 2. Florham Park, NJ: Macmillan Healthcare Information, 1987:153-163.
10. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47:1113-1124.
11. Apaydin H, Ahlskog JE, Parisi JE, et al. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002; 59:102-112.
12. Goetz CG, Pappert EJ, Blasucci LM, et al. Intravenous levodopa in hallucinating Parkinson's disease patients' high-dose challenge does not precipitate hallucinations. Neurology 1998; 50:515-517.
13. Perry EK, Marshall E, Kerwin J, et al. Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem 1990; 55:1454-1456.
14. Boeve BF, Silber MH, Ferman TJ, et al. REM sleep behavior disorder and degenerative dementia: an association likely reflecting Lewy body disease. Neurology 1998; 51:363-370.
15. Arnulf I, Nonnet A-M, Damier P, et al. Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology 2000; 55:281-288.
16. Rye DB. Contributions of the pedunculopontine region to normal and altered REM sleep. Sleep 1997; 20:757-788.
17. Perry EK, Morris CM, Court JA, et al. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience 1995; 64:385-395.
18. Perry EK, Irving D, Kerwin JM, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 1993; 7:69-79.
19. Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000; 157:4-15.
20. Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol 2002; 25:107-110.
21. Fabbrini G, Barbanti P, Aurilia C, et al. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci 2002; 23:41-43.
22. Ueki A, Iwado H, Shinjo H, Morita Y. Malignant syndrome caused by a combination of bromperidol and donepezil hydrochloride in a patient with probable dementia with Lewy bodies. Jpn J Geriatr 2001; 38:822-824.